Plain-English translation of NCT07375355 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study testing Scemblix (asciminib), a newer medication for chronic myeloid leukemia, in people who have been newly diagnosed. Researchers are collecting information before, during, and after treatment to understand how well the medication works and how safe it is for patients in everyday clinical practice.
While this medication has been studied in clinical trials, researchers want to learn more about how it performs when used in real hospitals and clinics, and how it helps newly diagnosed patients over time.
You likely qualify if…
You likely don't qualify if…
You would start taking the medication and visit the study clinic regularly so doctors can check your blood counts, monitor for side effects, and collect information about how you're doing. The study involves gathering your medical information at the beginning, during treatment, and for long-term follow-up to see how the medication helps over time. Most of your participation would happen during your regular medical visits at the clinic.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China
Sponsor
Novartis Pharmaceuticals
Enrollment target
~200 participants
Started
February 2026
Primary completion
December 2028
Age range
18 Years – 99 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.